Cargando…
Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells
Recent studies have demonstrated that acquisition of epithelial-to-mesenchymal transition (EMT) is associated with drug resistance in pancreatic cancer cells; however, the underlying mechanisms are not fully elucidated. Emerging evidence suggests that microRNAs play a crucial role in controlling EMT...
Autores principales: | Ma, Jia, Fang, Binbin, Zeng, Fanpeng, Ma, Cong, Pang, Haijie, Cheng, Long, Shi, Ying, Wang, Hui, Yin, Bin, Xia, Jun, Wang, Zhiwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359328/ https://www.ncbi.nlm.nih.gov/pubmed/25638153 |
Ejemplares similares
-
MiR-199 Reverses the Resistance to Gemcitabine in
Pancreatic Cancer by Suppressing Stemness through Regulating the Epithelial–Mesenchymal
Transition
por: Wei, Weitian, et al.
Publicado: (2021) -
Emodin reverses resistance to gemcitabine in pancreatic cancer by suppressing stemness through regulation of the epithelial‑mesenchymal transition
por: Wei, Weitian, et al.
Publicado: (2022) -
miR‐223‐3p targets FBXW7 to promote epithelial‐mesenchymal transition and metastasis in breast cancer
por: Wang, Yuli, et al.
Publicado: (2021) -
The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells
por: Wang, Rui, et al.
Publicado: (2015) -
miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer
por: Hiramoto, Hidekazu, et al.
Publicado: (2017)